Accredited Official Statistics
All data contained within this publication are Accredited Official Statistics, with the exception of Breast Cancer Referrals data.
Published by: Information & Analysis
Directorate, Department of Health
Statisticians: Brian Reilly, Jenny Finlay, Thomas Cash
& Liz Graham
Contact: statistics@health-ni.gov.uk
Reporting Period: 1 January 2024 - 31 March
2024
Publication Date: 9 July 2024
Date of Next Publication: 26 September 2024
Coverage: Northern Ireland
Frequency: Quarterly
On 9 November 2023 the South Eastern Health and Social Care (HSC) Trust launched ‘encompass’ - a new electronic patient record system. Its rollout across the other Trusts will follow on a phased basis throughout 2024/25. Consequently, as the Trust continues to transition to completely digitised health records at the time of this publication, the data which it has been possible to include for South Eastern HSC Trust from quarter ending December 2023 onwards are considered to be ‘official statistics in development’. Therefore, caution must be exercised when using these figures.
This statistical release presents information on waiting times for cancer services at hospitals in Northern Ireland and reports on the performance of the five Health and Social Care Trusts against the draft waiting time targets which state that:
Information is detailed on the number of patients who began treatment by HSC Trust for all targets and by tumour site for the 31 and 62 day targets. All of the data contained in this release are published on the NISRA Data Portal and in Excel file format to facilitate secondary analysis. These are available at the following links:
https://data.nisra.gov.uk/product/HWTS
• In the quarter ending March 2024, 2,949 patients started their first definitive treatment, 6.1% (170) more than in the previous quarter (2,779), and 5.9% (165) more than in the same quarter last year (2,784).
• 86.5% (2,551) of those patients started treatment within 31 days of a decision to treat, compared with 88.6% (2,463) in the previous quarter and 87.8% (2,445) in the same quarter last year.
62 Day Target figures do not include the South Eastern Trust as validated data were not available at the time of publication.
• In the quarter ending March 2024, 1,111 patients started their first definitive treatment at the Belfast, Northern, Southern and Western Trusts, 3.3% (35) more than in the previous quarter (1,076), and 1.2% (13) fewer than in the same quarter last year (1,124).
• 29.8% (331.5) of those patients started treatment within 62 days, compared with 30.0% (323) in the previous quarter and 33.5% (377) in the same quarter last year.
• In the quarter ending March 2024, there were 3,605 patients seen by a breast cancer specialist following an urgent referral for suspect breast cancer, 1.9% (68) more than in the previous quarter (3,537), and 0.9% (32) fewer than in the same quarter last year (3,637).
• 34.1% (1,230) of those patients were seen within 14 days of their urgent referral for breast cancer, compared with 35.5% (1,254) in the previous quarter and 84.2% (3,062) in the same quarter last year.
Target: At least 98% of patients urgently referred with a suspected cancer should begin their first definitive treatment within 31 days of a decision to treat.
In the quarter ending March 2024, 2,949 patients started
treatment following a decision to treat, of which 86.5% (2,551) started
treatment within 31 days. The target was not achieved at a regional
level.
The number of patients starting treatment increased by 6.1% (170) since last quarter, and increased by 5.9% (165) from the same quarter last year.
The percentage of patients starting treatment within 31 days decreased from 88.6% in the previous quarter and decreased from 87.8% in the same quarter last year.
The Western HSC Trust met the target of 98% percent of patients starting treatment within 31 days (98.8%).
Figure 1: Line charts illustrating the number of patients starting treatment following a decision to treat each quarter from June 2008 to March 2024 indicating the percentage and number within the 31 day target.
Figures in this section do not include the South Eastern Trust as validated data were not available at time of publication.
Of tumour sites with more than 50 patients in the Belfast, Northern, Southern and Western Trusts starting treatment during the quarter ending March 2024, Haematological Cancers had the highest percentage treated within 31 days (98.9%) while Urological Cancer had the lowest (78.0%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 31 Days | % Within 31 Days change since last quarter |
---|---|---|---|---|
Urological Cancer | 513 | 47 | 78.0% | -4.2 |
Breast Cancer | 344 | 17 | 87.5% | -4.9 |
Lower Gastrointestinal Cancer | 300 | 41 | 88.0% | -1.6 |
Lung Cancer | 269 | -7 | 86.2% | -9.4 |
Skin Cancers | 230 | -18 | 89.1% | 1.6 |
Upper Gastrointestinal Cancer | 208 | 5 | 89.4% | 0.3 |
Haematological Cancers | 187 | 17 | 98.9% | 0.1 |
Gynaecological Cancers | 128 | -15 | 85.2% | 13.1 |
Head/Neck Cancer | 112 | -1 | 91.1% | -4.5 |
Brain/Central Nervous System | 41 | 12 | 100.0% | 0.0 |
Other | 38 | 0 | 94.7% | -2.6 |
Sarcomas | 15 | 6 | 86.7% | -13.3 |
Figures in this section do not include the South Eastern Trust as validated data were not available at the time of publication.
Target: At least 95% of patients urgently referred by a GP with suspected cancer should begin their first definitive treatment within 62 days.
Note: Cases in which a
patient was initially referred to one Trust for assessment and then
subsequently transferred to another Trust for treatment are split evenly
and counted as being 0.5 from each Trust. During the quarter ending
March 2024 there were 63 patients that were seen first at South Eastern
Trust that were transferred to the other Trusts for treatment. This
results in a total count of 1079.5 cases (1,111 - (63 * 0.5)) associated
with the four Trusts being reported.
During the quarter ending March 2024, 1,111 patients started treatment following an urgent GP referral for suspect cancer, of which 29.8% (331.5) started treatment within 62 days. Of these patients, 63 were first seen in the South Eastern Trust.
The number of patients treated increased by 3.3% (35) since last quarter, and decreased by 1.2% (13) since the same quarter last year.
The percentage of patients starting treatment within 62 days decreased from 30.0% in the previous quarter and decreased from 33.5% in the same quarter last year.
Figures in this section do not include the South Eastern Trust as validated data were not available at time of publication.
The Western HSC Trust reported the highest percentage of patients starting treatment within 62 days at 39.8% (113.5 of 285). The lowest percentage was reported by the Belfast HSC Trust at 25.6% (104.5 of 408.5).
Note: In June 2009 the target was increased from 75% to 95%
Figure
2: Line charts illustrating the number of patients starting treatment
following an urgent GP referral each quarter from June 2008 to March
2024 indicating the percentage and number within the 62 day target.
Figures in this section do not include the South Eastern Trust as validated data were not available at time of publication.
Of tumour sites with more than 50 patients in the Belfast, Northern, Southern and Western Trusts starting treatment during the quarter ending March 2024, Lung Cancer had the highest percentage treated within 62 days (44.9%) while Lower Gastrointestinal Cancer had the lowest (20.5%).
Tumour Site | Total Treated | Change Since Last Quarter | % Within 62 Days | % Within 62 Days change since last quarter |
---|---|---|---|---|
Urological Cancer | 350 | 23 | 21.4% | 2.8 |
Breast Cancer | 162 | 23 | 40.7% | -13.9 |
Skin Cancers | 157 | 3 | 27.4% | -10.3 |
Lower Gastrointestinal Cancer | 127 | -4 | 20.5% | 4.4 |
Other | 82 | 71 | 24.4% | -21.1 |
Lung Cancer | 78 | 13 | 44.9% | 3.3 |
Upper Gastrointestinal Cancer | 67 | -12 | 38.8% | 9.7 |
Head/Neck Cancer | 50 | -2 | 41.0% | 23.7 |
Haematological Cancers | 38 | -6 | 52.6% | -8.7 |
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Target: All urgent breast cancer referrals should be seen within 14 days.
During the quarter ending March 2024, 3,605 patients were seen by a breast cancer specialist following an urgent referral, of which 34.1% (1,230) were seen within 14 days.
The number of patients seen increased by 1.9% (68) from last quarter, and decreased by 0.9% (32) from the same quarter last year.
The percentage of patients seen within 14 days decreased from 35.5% in the previous quarter and decreased from 84.2% in the same quarter last year.
No HSC Trust achieved the target of seeing all urgent breast cancer referrals within 14 days. Western HSC Trust saw the highest percentage of patients within 14 days (98.6%).
Figure 3: Line charts illustrating the number of urgent breast cancer referrals seen each quarter from June 2008 to March 2024 indicating the percentage and number seen within the 14 day target.
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Adding the number of referrals for suspect breast cancer at each HSC Trust to make a Northern Ireland total may inflate the ‘true demand’ on the service regionally as any referrals transferred from one Trust to another will create a duplicate referral.
During the quarter ending March 2024, 6,861 referrals were received by HSC Trusts for suspect breast cancer, of which 70.1% (4,810) were classified as urgent.
During the quarter ending March 2024, the highest number of referrals (1,800) were received by the Northern HSC Trust for suspect breast cancer, of which 60.9% (1,097) were classified as urgent. The South Eastern HSC Trust received the lowest number of breast cancer referrals (1,038), however 81.2% (843) of these were urgent referrals.
The total of 6,861 breast referrals represents approximately 6,332 individual patients referred for breast cancer treatment during the quarter ending March 2024.
Approximately 8.3% of patients (527 out of 6,332) in Northern Ireland were referred more than once for breast cancer treatment during the quarter ending March 2024.
A patient may be referred more than once if they are transferred to another consultant or a different Trust, or if they did not attend first treatment appointment and have been referred again.
Across each HSC Trust the number of patients referred and the percentage categorised as urgent has remained broadly steady since June 2016, with the exception of a reduction in the number of routine referrals during the quarter ending June 2020.
Figure 4: Line charts illustrating the number of breast cancer referrals received each quarter from June 2016 to March 2024 indicating the number and percentage that were classified as urgent.
Data used to report on the 31 and 62 day targets are sourced from the Cancer Patient Pathway System (CaPPS), the data system used to administer cancer treatment services within Health and Social Care Trusts in Northern Ireland.
Data used to report on the breast cancer activity and referrals are sourced from the Patient Administration System (PAS), an administrative system used to manage, record and monitor hospital waiting lists within Health and Social Care Trusts in Northern Ireland. Hospital Information Branch introduced this methodology for the collection of breast cancer waiting time information in April 2017. Information was originally sourced from the Departmental SDR2 Return in aggregate format.
Data for the South Eastern HSC Trust from 9 November 2023 onwards are sourced from ‘encompass’, which is a new electronic patient record system. These data are considered to be ‘official statistics in development’. The rollout of encompass across the other Trusts will follow on a phased basis throughout 2024/25.
Regionally consistent data collection for cancer waiting times has been in place since April 2008. Cancer referrals data has been collected from April 2016.
All data presented in this publication have been validated and quality assured by Hospital Information Branch in conjunction with HSC Trusts.
The 31 day target relates to all patients who received a first definitive treatment for cancer during each of the three months covered in the publication, irrespective of their source or type of referral.
This is measured from the date on which the patient and the clinician agree the planned treatment and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
The 62 day target relates to patients who received a first definitive treatment for cancer during each of the three months covered in the publication, following an urgent referral for suspect cancer from a General Practitioner (GP) or a routine GP referral that has subsequently been reclassified as urgent by a cancer specialist. Referrals from sources other than a GP, routine referrals and patients who have not been given an ICD 10 diagnosis are excluded.
This is measured from the date an initial urgent GP referral for suspect cancer is received by the HSC Trust and ends on the date the patient receives their first definitive treatment for cancer. Adjustments are made to the completed waiting time in the event of a patient cancelling or self-deferring treatment or because of suspension for either medical or social reasons.
Prior to June 2009, the target relating to waiting time for treatment following an urgent GP referral for suspect cancer was that at least 75% of patients urgently referred with a suspect cancer should begin their first definitive treatment within 62 days of referral.
Breast cancer activity reported against the 14 day target relates to all urgent referrals for suspect breast cancer that were first seen during each of the three months covered in the publication, irrespective of the source of referral. Figures include routine referrals that have subsequently been reclassified by a breast specialist as urgent and exclude urgent referrals reclassified as routine.
This is measured from the date an initial breast cancer referral is first received by the HSC Trust, and ends on the date that the patient attends their first outpatient appointment with a breast cancer specialist. Adjustments are made to the completed waiting time in the event of a patient cancelling, self-deferring or failing to attend a first outpatient appointment.
Data users should note that breast cancer referrals statistics are not designated as Accredited Official Statistics.
Figures provided in the Breast Cancer Referrals section reflect all new referrals received for suspect breast cancer irrespective of the source or urgency of referral. Referrals for breast cancer can be for advice, assessment or both.
The measurement of a patient’s waiting time against the 62 day target includes cases in which a patient was initially referred to one Trust for consultant assessment but was then subsequently transferred to another Trust for treatment. In such cases, the responsibility for that patient is shared, with 0.5 allocated to the Trust where the patient was first assessed and 0.5 to the Trust of first treatment. For example, if a patient is initially referred for assessment in the Southern HSC Trust and is then transferred to the Belfast HSC Trust where they receive treatment 70 days after their initial GP referral, both the Southern and Belfast HSC Trusts will report 0.5 of a patient treated who waited over 62 days.
For the 31 day target, all patients are reported against the Trust providing their treatment.
Breast cancer activity is reported against the Trust the patient is referred to.
Breast cancer referrals are reported against the Trust the patient is referred to. However, as some referrals will be transferred to another Trust, this referral can be recorded under both the intial Trust and the Trust that has accepted transfer of the patient.
The 31 and 62 day targets relate to patients who received a first definitive treatment for cancer having been given an ‘International Classification of Diseases 10’ (ICD 10) diagnosis. Patients that have not been given an ICD 10 diagnosis are excluded.
Tumour sites are assigned by aggregation of applicable ICD 10 codes.
Data for all cancers are included except for basal cell carcinoma.
A breakdown of these statistics by Trust and tumour site is not routinely published due to the relatively small number of patients involved and disclosure control needed to preserve the privacy of individual patients.
These statistics include patients living outside Northern Ireland and privately funded patients seen in Health and Social Care hospitals in Northern Ireland.
Technical guidance and definitions, as well as notes on how to use the date contained within this statistical release are available at the following link:
https://www.health-ni.gov.uk/publications/cancer-waiting-times-guidance-and-returns
Data detailed in this publication are also available on the NISRA Data Portal and in Excel file format to aid secondary analysis.
The Data Portal allows users to filter results, plot interactive charts and read data via API queries and to download data in CSV, XLSX, JSON-stat and PX formats. It can be accessed at the following link: https://data.nisra.gov.uk/product/HWTS
XLSX files are available to download at the following link: https://www.health-ni.gov.uk/publications/northern-ireland-waiting-time-statistics-cancer-waiting-times-january-march-2024.
Statistics on waiting times for inpatients, outpatients, diagnostic services and emergency care are available at the following link: https://www.health-ni.gov.uk/topics/doh-statistics-and-research/hospital-waiting-times-statistics
Accredited Official Statistics are called National Statistics in the Statistics and Registration Service Act 2007. These official statistics were independently reviewed by the Office for Statistics Regulation (OSR) in 2011. They comply with the standards of trustworthiness, quality and value in the Code of Practice for Statistics and should be labelled ‘Accredited Official Statistics’ (designation awarded in December 2013).
Our statistical practice is regulated by the OSR, which sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to.
You are welcome to contact us directly with any comments about how we meet these standards.
Alternatively, you can contact OSR by emailing regulation@statistics.gov.uk or via the OSR website Office for Statistics Regulation (https://osr.statisticsauthority.gov.uk).
It is the Department of Health’s responsibility, as the producer, to maintain compliance with the standards expected of Accredited Official Statistics. If we become concerned about whether these statistics are still meeting the appropriate standards, we will discuss any concerns with the OSR promptly. Accredited Official Statistics status can be removed at any point when the highest standards are not maintained and reinstated when standards are restored.
Find out more about the Code of Practice for Statistics at: https://code.statisticsauthority.gov.uk/
Find out more about Official Statistics at: https://uksa.statisticsauthority.gov.uk/about-the-authority/uk-statistical-system/types-of-official-statistics/
Please contact Hospital Information Branch for assistance with accessibility requirements or alternative formats. Email: statistics@health-ni.gov.uk
This publication is Crown copyright and may be reproduced free of charge in any format or medium. Any material used must be acknowledged, and the title of the publication specified.